var data={"title":"Reversible posterior leukoencephalopathy syndrome","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Reversible posterior leukoencephalopathy syndrome</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/contributors\" class=\"contributor contributor_credentials\">Terry A Neill, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/contributors\" class=\"contributor contributor_credentials\">Michael J Aminoff, MD, DSc</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/contributors\" class=\"contributor contributor_credentials\">Janet L Wilterdink, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Apr 29, 2015.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H712827215\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Reversible posterior leukoencephalopathy syndrome (RPLS) is a clinical radiographic syndrome of heterogeneous etiologies that are grouped together because of similar findings on neuroimaging studies. It is also often referred to as:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Posterior reversible encephalopathy syndrome (PRES)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Reversible posterior cerebral edema syndrome</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Posterior leukoencephalopathy syndrome</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hyperperfusion encephalopathy</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Brain capillary leak syndrome</p><p/><p>None of these names is completely satisfactory; the syndrome is not always reversible, and it is often not confined to either the white matter or the posterior regions of the brain.</p><p>Although described in various specific case reports for some time, it was first codified as a single named syndrome in a 1996 case series [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/1\" class=\"abstract_t\">1</a>]. This described a clinical syndrome of insidious onset of headache, confusion or decreased level of consciousness, visual changes, and seizures, which was associated with characteristic neuroimaging findings of posterior cerebral white matter edema.</p><p>RPLS has been described in a number of medical conditions, with hypertensive encephalopathy, eclampsia, and the use of cytotoxic and immunosuppressant drugs being the most common. Prompt recognition and treatment is important in preventing the permanent damage that can occur in this otherwise typically reversible condition.</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Reversible posterior leukoencephalopathy syndrome (RPLS) is increasingly recognized and reported in case reports and case series; however, the incidence of RPLS is not known.</p><p>Patients in all age groups appear susceptible; reported cases exist in patients as young as two years and as old as 90 years [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/2-7\" class=\"abstract_t\">2-7</a>]. Case series suggest that RPLS is more common in women, even when patients with eclampsia are excluded [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/1,8-10\" class=\"abstract_t\">1,8-10</a>].</p><p>Hypertensive disorders, renal disease, and immunosuppressive therapies are risk factors for this disorder.</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The pathogenesis of reversible posterior leukoencephalopathy syndrome (RPLS) remains unclear, but it appears to be related to disordered cerebral autoregulation and endothelial dysfunction [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/1\" class=\"abstract_t\">1</a>]. Because of the heterogeneous nature of this disorder, it may be that different mechanisms are etiologically important in different clinical situations.</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Autoregulatory failure</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Normal autoregulation maintains constant cerebral blood flow over a range of systemic blood pressure, by means of arteriolar constriction and dilatation (<a href=\"image.htm?imageKey=NEURO%2F67583\" class=\"graphic graphic_figure graphicRef67583 \">figure 1</a> and <a href=\"image.htm?imageKey=NEPH%2F57676\" class=\"graphic graphic_figure graphicRef57676 \">figure 2</a>) [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/11,12\" class=\"abstract_t\">11,12</a>]. As the upper limit of cerebral autoregulation is exceeded, arterioles dilate and cerebral blood flow increases in a pressure-passive manner with rises in systemic blood pressure. The resulting brain hyperperfusion, particularly in arterial border zones, may lead to breakdown of the blood brain barrier allowing extravasation of fluid and blood products into the brain parenchyma [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/11\" class=\"abstract_t\">11</a>].</p><p>The rate of blood pressure elevation is likely to be important. In chronic hypertension, adaptive vascular changes &quot;reset&quot; the range of autoregulation to higher systemic blood pressures (<a href=\"image.htm?imageKey=NEPH%2F57676\" class=\"graphic graphic_figure graphicRef57676 \">figure 2</a>). As a result, patients with RPLS in the setting of longstanding hypertension may have markedly elevated blood pressures, while less severe elevations, even normal blood pressures, are associated with RPLS in other settings. Children appear particularly vulnerable to RPLS at lower blood pressures than adults [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/2,13\" class=\"abstract_t\">2,13</a>].</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Cerebral ischemia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Alternatively, in severe cases, it has been postulated that disordered cerebral autoregulation may lead to reactive focal vasoconstriction, thereby resulting in local hypoperfusion, cytotoxic edema, and cerebral infarction [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/8,14,15\" class=\"abstract_t\">8,14,15</a>]. It is also possible that the cerebral infarctions, which uncommonly occur in RPLS, could result from compression of microcirculation from the mass effect of vasogenic edema. Some patients, but not all, have demonstrable vasoconstriction on radiologic imaging [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/10,16\" class=\"abstract_t\">10,16</a>]. Also, radionuclide studies have demonstrated perfusion deficits in some patients with RPLS [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/17,18\" class=\"abstract_t\">17,18</a>]. (See <a href=\"#H15\" class=\"local\">'Neuroimaging'</a> below.)</p><p>However, ischemia is not believed to play the major pathophysiologic role in most patients with RPLS. Pathologic data, while quite limited, have not reported ischemia or infarction [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/19\" class=\"abstract_t\">19</a>]; increased rather than decreased perfusion can also be seen on radionuclide imaging studies [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/20\" class=\"abstract_t\">20</a>], and many patients with RPLS do not have demonstrable vascular narrowing. Most persuasive in this regard is that most patients have complete reversibility of clinical and neuroradiographic findings.</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Endothelial dysfunction</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Endothelial dysfunction has also been implicated in the pathophysiology of RPLS, especially in cases associated with preeclampsia or cytotoxic therapies [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/1,2\" class=\"abstract_t\">1,2</a>]. The latter may have direct toxicity on vascular endothelium, leading to capillary leakage, and blood-brain barrier disruption and axonal swelling, which may then trigger vasogenic edema [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/1,21\" class=\"abstract_t\">1,21</a>]. RPLS associated with these therapies may occur in normotensive individuals and with nontoxic levels of these drugs [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/2\" class=\"abstract_t\">2</a>].</p><p>In preeclampsia, markers of endothelial cell dysfunction (lactate dehydrogenase, abnormal red blood cell morphology) typically arise prior to the clinical syndrome and correlate better with the extent of cerebral edema than do blood pressure changes [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/22-24\" class=\"abstract_t\">22-24</a>]. More specific markers of endothelial dysfunction that have also been found to be released in patients with preeclampsia include fibronectin, tissue plasminogen activator, thrombomodulin, endothelin-1, and, in particular, von Willebrand factor [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/25-27\" class=\"abstract_t\">25-27</a>]. Secretion of trophoblastic cytotoxic factors originating from a poorly perfused fetal unit may provide the initial stimulus [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/28\" class=\"abstract_t\">28</a>]. (See <a href=\"topic.htm?path=preeclampsia-pathogenesis\" class=\"medical medical_review\">&quot;Preeclampsia: Pathogenesis&quot;</a>.)</p><p>Markers of endothelial cell dysfunction have also been reported in patients with RPLS in other clinical settings including chronic renal failure, lupus nephritis, and hemolytic uremic syndrome [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/2\" class=\"abstract_t\">2</a>]. While cases of RPLS associated with thrombotic thrombocytopenic purpura usually occur with coexistent hypertension and renal failure [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/29\" class=\"abstract_t\">29</a>], one reported case in the absence of these complications suggests a primary role for endothelial injury in this setting as well [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/30\" class=\"abstract_t\">30</a>].</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Other mechanisms</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In some clinical settings, uremia, sepsis, hypomagnesemia, and other metabolic disturbances have been implicated [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/8,21\" class=\"abstract_t\">8,21</a>]. These factors may mediate their effect on the vascular endothelium or other sites of vasogenic control. Fluid overload may also contribute to cerebral edema in some patients.</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Anatomic distribution</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The combination of acute hypertension and endothelial damage results in hydrostatic edema, a specific form of vasogenic edema characterized by the forced leakage of serum through capillary walls and into the brain interstitium, which, if severe enough, will be radiographically evident. Unregulated vascular injury to blood-brain barrier endothelium leads to edema, protein extravasation, and fibrinoid necrosis [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/31\" class=\"abstract_t\">31</a>]. The cortex, structurally more tightly packed than the white matter, resists accumulation of edema, hence predilection of abnormalities to be seen in the white matter [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/32\" class=\"abstract_t\">32</a>].</p><p>The primary involvement of posterior brain regions is not well understood. One possibility involves the regional heterogeneity of the sympathetic innervation of the intracranial arterioles, which has been shown to protect the brain from marked increases in blood pressure [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/33\" class=\"abstract_t\">33</a>]. A histochemical study revealed a greater concentration of adrenergic nerves around pial and intracerebral vessels in the anterior circulation than posteriorly [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/34\" class=\"abstract_t\">34</a>]. This observation may explain why the hyperperfusion and edema is mainly seen in the posterior circulation in RPLS.</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h1\">ASSOCIATED CONDITIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A wide variety of medical conditions have been implicated as causes of reversible posterior leukoencephalopathy syndrome (RPLS) (<a href=\"image.htm?imageKey=NEURO%2F51758\" class=\"graphic graphic_table graphicRef51758 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/35-37\" class=\"abstract_t\">35-37</a>]. Comorbid medical conditions (ischemic bowel disease, sepsis, hyponatremia, fever, proteinuria) can exacerbate neurologic deterioration in patients and are therefore important to identify [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/8\" class=\"abstract_t\">8</a>]. Some conditions (eg, autoimmune disease) may be associated with RPLS either because of their secondary effects on blood pressure or because of medications used to treat them [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/35,38\" class=\"abstract_t\">35,38</a>]. The more common causes of RPLS will be reviewed here.</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Hypertension</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In acute, severe hypertension, RPLS results from acute elevation of blood pressure beyond the upper limits of cerebral autoregulation [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/1\" class=\"abstract_t\">1</a>]. The neurologic syndrome in hypertensive encephalopathy is now believed to be caused by vasogenic edema from this breakthrough of autoregulation [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/20,39-41\" class=\"abstract_t\">20,39-41</a>].</p><p>Rapidly developing, fluctuating, or intermittent hypertension carries a particular risk for hypertensive encephalopathy [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/42\" class=\"abstract_t\">42</a>]. Patients with untreated or undertreated chronic hypertension, renal failure, or preeclampsia-eclampsia are particular populations where this may be seen. (See <a href=\"topic.htm?path=moderate-to-severe-hypertensive-retinopathy-and-hypertensive-encephalopathy-in-adults\" class=\"medical medical_review\">&quot;Moderate to severe hypertensive retinopathy and hypertensive encephalopathy in adults&quot;</a>.)</p><p>The percent elevation of blood pressure over baseline, as well as the severity of the hypertension, are important [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/11,12\" class=\"abstract_t\">11,12</a>]. Therefore, while approximately 75 percent of patients have moderate to severe hypertension at presentation, RPLS may occur in normotensive patients [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/43\" class=\"abstract_t\">43</a>]. Although RPLS is described in malignant hypertension alone, it appears to be more common in patients with comorbid conditions, such as systemic lupus erythematosus [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/20,41,44,45\" class=\"abstract_t\">20,41,44,45</a>], cryoglobulinemia [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/46\" class=\"abstract_t\">46</a>], or hemolytic uremic syndrome [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/41,47,48\" class=\"abstract_t\">41,47,48</a>], and in patients treated with <a href=\"topic.htm?path=cyclosporine-ciclosporin-drug-information\" class=\"drug drug_general\">cyclosporine</a> [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/49\" class=\"abstract_t\">49</a>] or <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a>&nbsp;[<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/21\" class=\"abstract_t\">21</a>]. The fact that renal failure appears to be particularly prevalent among hypertensive patients with RPLS suggests a role for either fluid overload, electrolyte disturbances, or uremia [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/50\" class=\"abstract_t\">50</a>].</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h3\">Eclampsia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most investigators believe hypertensive encephalopathy and preeclampsia share similar mechanisms [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/17,51\" class=\"abstract_t\">17,51</a>]. In many patients, the syndrome occurs during the puerperium rather than during pregnancy [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/52\" class=\"abstract_t\">52</a>]. Some suggest that RPLS (typical clinical syndrome and neuroimaging findings) could be considered an indicator of eclampsia, even when the other features of eclampsia (proteinuria, hypertension) are not present [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/53\" class=\"abstract_t\">53</a>]. Blood pressures in patients with preeclampsia and eclampsia who develop RPLS are generally lower than in patients who develop RPLS in other settings [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/22\" class=\"abstract_t\">22</a>]. (See <a href=\"topic.htm?path=preeclampsia-pathogenesis\" class=\"medical medical_review\">&quot;Preeclampsia: Pathogenesis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Immunosuppressive therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>RPLS occurs in patients prescribed immunosuppressive and immunomodulatory therapies for malignancy, transplantation, rheumatologic conditions, and other indications. A partial list of these agents is provided in the Table (<a href=\"image.htm?imageKey=NEURO%2F51758\" class=\"graphic graphic_table graphicRef51758 \">table 1</a>). </p><p>The neurotoxic effects of these therapies are well known but still poorly understood. Toxic levels of medications are not required for the development of RPLS, and prior exposure to the drug does not appear to be protective [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/2\" class=\"abstract_t\">2</a>]. Even after several months of exposure to the drug, patients with therapeutic levels can be symptomatic [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/2\" class=\"abstract_t\">2</a>]. Patients may be normotensive, but the blood pressure is usually elevated over baseline [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/1,54\" class=\"abstract_t\">1,54</a>].</p><p><a href=\"topic.htm?path=cyclosporine-ciclosporin-drug-information\" class=\"drug drug_general\">Cyclosporine</a> is one of the more common cytotoxic therapies associated with the neurologic deficits of RPLS. After renal toxicity, neurotoxicity is the most serious side effect with cyclosporine, affecting 25 percent to 59 percent of transplant patients [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/55\" class=\"abstract_t\">55</a>]. Hypomagnesemia, hypocholesterolemia, the vasoactive agent endothelin, and hypertension have all been implicated in facilitating cyclosporine neurotoxicity [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/55\" class=\"abstract_t\">55</a>]. Cyclosporine may in turn exacerbate hypertension by inhibiting nitric oxide production [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/56\" class=\"abstract_t\">56</a>]. The mechanism of cyclosporine cellular injury is thought to be mediated through mitochondrial dysfunction; this is supported by the similarity of the symptoms of cyclosporine neurotoxicity and mitochondrial encephalopathy [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/57\" class=\"abstract_t\">57</a>]. (See <a href=\"topic.htm?path=pharmacology-of-cyclosporine-and-tacrolimus\" class=\"medical medical_review\">&quot;Pharmacology of cyclosporine and tacrolimus&quot;</a>.)</p><p>These concepts are illustrated in a study that assessed the factors responsible for the neurotoxic effects of <a href=\"topic.htm?path=cyclosporine-ciclosporin-drug-information\" class=\"drug drug_general\">cyclosporine</a> [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/49\" class=\"abstract_t\">49</a>]. Sixteen patients with neurologic injury attributed to cyclosporine therapy were evaluated by neuroimaging as well as various clinical and laboratory data. Systemic hypertension was the only major factor associated with the neurotoxic effects of cyclosporine, although microangiopathic hemolytic anemia, thrombocytopenia, and hypoalbuminemia were common. Clinical and radiologic findings resembled those of hypertensive encephalopathy. Elevated serum cyclosporine levels were not related to the onset of neurologic symptoms.</p><p>While RPLS with <a href=\"topic.htm?path=cyclosporine-ciclosporin-drug-information\" class=\"drug drug_general\">cyclosporine</a> use is most often reported, RPLS has been associated with other agents, including <a href=\"topic.htm?path=tacrolimus-drug-information\" class=\"drug drug_general\">tacrolimus</a>, <a href=\"topic.htm?path=sirolimus-drug-information\" class=\"drug drug_general\">sirolimus</a>, <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a>, and interferon therapies, and agents that target angiogenesis such as <a href=\"topic.htm?path=bevacizumab-including-biosimilars-of-bevacizumab-drug-information\" class=\"drug drug_general\">bevacizumab</a>, a monoclonal antibody directed against vascular endothelial growth factor (VEGF) and small molecule tyrosine kinase inhibitors that target the VEGF receptor (<a href=\"topic.htm?path=pazopanib-drug-information\" class=\"drug drug_general\">pazopanib</a>, <a href=\"topic.htm?path=sorafenib-drug-information\" class=\"drug drug_general\">sorafenib</a>, <a href=\"topic.htm?path=sunitinib-drug-information\" class=\"drug drug_general\">sunitinib</a>) (<a href=\"image.htm?imageKey=NEURO%2F51758\" class=\"graphic graphic_table graphicRef51758 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/1,21,58-64\" class=\"abstract_t\">1,21,58-64</a>]. The mechanisms are thought to be similar. (See <a href=\"topic.htm?path=toxicity-of-molecularly-targeted-antiangiogenic-agents-non-cardiovascular-effects#H1651228679\" class=\"medical medical_review\">&quot;Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects&quot;, section on 'Reversible posterior leukoencephalopathy and brain capillary leak syndrome'</a>.)</p><p class=\"headingAnchor\" id=\"H271180842\"><span class=\"h2\">Others</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A number of other, possibly related conditions have been described in case reports of patients with RPLS. A partial list is provided in the Table (<a href=\"image.htm?imageKey=NEURO%2F51758\" class=\"graphic graphic_table graphicRef51758 \">table 1</a>).</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The clinical syndrome of reversible posterior leukoencephalopathy syndrome (RPLS) is characterized by [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/36\" class=\"abstract_t\">36</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Headaches</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Altered consciousness</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Visual disturbances</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Seizures</p><p/><p>The headache is typically constant, nonlocalized, moderate to severe, and unresponsive to analgesia [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/10\" class=\"abstract_t\">10</a>].</p><p>Altered consciousness ranges from mild somnolence to confusion and agitation, progressing to stupor or coma in extreme cases [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/1,10,62,65\" class=\"abstract_t\">1,10,62,65</a>].</p><p>Seizures are often the presenting manifestation [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/1,7,50,66\" class=\"abstract_t\">1,7,50,66</a>]. Seizures are usually generalized tonic clonic; they may begin focally and often recur. Status epilepticus has been reported [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/63,67\" class=\"abstract_t\">63,67</a>]. Preceding visual loss or visual hallucinations suggest occipital lobe origin in some patients. Only a minority of patients, usually those with milder disease, are seizure free [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/2\" class=\"abstract_t\">2</a>].</p><p>Visual perception abnormalities are often detectable. Hemianopia, visual neglect, auras, visual hallucinations, and cortical blindness may occur [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/1,68\" class=\"abstract_t\">1,68</a>]. The latter may be accompanied by denial of blindness (Anton's syndrome).</p><p>The funduscopic examination is often normal, particularly in eclamptic and chronically hypertensive patients, but papilledema may be present with accompanying flame-shaped retinal hemorrhages and exudates. The deep tendon reflexes are frequently brisk with Babinski signs often present [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/10\" class=\"abstract_t\">10</a>]. A few patients may have weakness and incoordination of the limbs [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/1,8,69\" class=\"abstract_t\">1,8,69</a>]. Other focal neurologic deficits are rare.</p><p>Hypertension is frequent but not invariable. The hypertensive crisis may precede the neurologic syndrome by 24 hours or longer [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/2,10\" class=\"abstract_t\">2,10</a>].</p><p>Relatively unusual patients with symptoms referable to the upper cervical spinal cord (limb weakness, bladder dysfunction), along with one or more of the symptoms above have also been described [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/70\" class=\"abstract_t\">70</a>].</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h1\">NEUROIMAGING</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Neuroimaging is essential to the diagnosis of reversible posterior leukoencephalopathy syndrome (RPLS). Typical findings are symmetrical white matter edema in the posterior cerebral hemispheres, particularly the parieto-occipital regions, but variations do occur [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/35,36,71\" class=\"abstract_t\">35,36,71</a>]. Because the neuroradiographic findings after seizures or other neurologic conditions can be similar to those seen in RPLS, repeat neuroimaging may be necessary. With treatment, resolution of findings on neuroimaging within days to weeks is expected.</p><p>Some important localization considerations for RPLS are:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The calcarine and paramedian parts of the occipital lobe are usually spared, helping to distinguish RPLS from bilateral posterior cerebral infarctions [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/1\" class=\"abstract_t\">1</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Involvement of the cerebellum and brainstem is common. Isolated or predominant posterior fossa lesions, while uncommon, are increasingly described (sometimes called hypertensive brainstem encephalopathy) [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/2,36,50,72-77\" class=\"abstract_t\">2,36,50,72-77</a>]. Rarely, changes are seen in the cervical spinal cord [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/70,78,79\" class=\"abstract_t\">70,78,79</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Lesions of the anterior cortex do occur but tend to occur in more severe cases, usually with edema being present in the posterior circulation territories [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/2,36,50\" class=\"abstract_t\">2,36,50</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Although abnormalities primarily affect the subcortical white matter, the cortex and basal ganglia may be involved [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/50,71,80,81\" class=\"abstract_t\">50,71,80,81</a>]. In some milder cases, abnormalities have been more predominantly seen in the gray matter suggesting that edema may begin in the cortex [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/2,72\" class=\"abstract_t\">2,72</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The distribution of abnormalities is usually not confined to a single vascular territory [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/35\" class=\"abstract_t\">35</a>].</p><p/><p>Neuroradiographic abnormalities of RPLS are often apparent on computed tomography (CT) scans [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/82\" class=\"abstract_t\">82</a>] but are best depicted by magnetic resonance imaging (MRI) (<a href=\"image.htm?imageKey=NEURO%2F79338\" class=\"graphic graphic_diagnosticimage graphicRef79338 \">image 1</a>) [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/20\" class=\"abstract_t\">20</a>]. The most commonly observed abnormalities on MRI are punctate or confluent areas of increased signal on proton density and T2-weighted images [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/35\" class=\"abstract_t\">35</a>]. Other typical MRI findings include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Fluid-attenuated inversion recovery (FLAIR) sequences improve sensitivity and detect subtle peripheral lesions, showing cortical lesions to be more common than once thought by T2 imaging (<a href=\"image.htm?imageKey=NEURO%2F79338\" class=\"graphic graphic_diagnosticimage graphicRef79338 \">image 1</a>) [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/2,72\" class=\"abstract_t\">2,72</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Gyriform signal enhancement, reflecting disruption of the blood-brain barrier, can be present following the administration of gadolinium (<a href=\"image.htm?imageKey=NEURO%2F79338\" class=\"graphic graphic_diagnosticimage graphicRef79338 \">image 1</a>) [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/20\" class=\"abstract_t\">20</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Petechial and large parenchymal hemorrhages have also been described [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/20,50,82\" class=\"abstract_t\">20,50,82</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In most follow-up studies, the abnormalities have partially or completely resolved suggesting edema rather than infarction (<a href=\"image.htm?imageKey=NEURO%2F56979\" class=\"graphic graphic_diagnosticimage graphicRef56979 \">image 2</a>) [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/1,35,50\" class=\"abstract_t\">1,35,50</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Diffusion-weighted imaging (DWI) aids in the distinction of RPLS from top of the basilar stroke. Vasogenic edema is usually visualized as a hypo- or isointense signal on DWI (sometimes slightly hyperintense due to T2 shine through) and increased signal on apparent diffusion coefficient (ADC) maps (<a href=\"image.htm?imageKey=NEURO%2F56979\" class=\"graphic graphic_diagnosticimage graphicRef56979 \">image 2</a>) [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/2,9,72,80\" class=\"abstract_t\">2,9,72,80</a>]. Acute cerebral infarction produces marked hyperintensity on DWI and hypointensity on ADC maps (<a href=\"image.htm?imageKey=NEURO%2F70704\" class=\"graphic graphic_diagnosticimage graphicRef70704 \">image 3</a>). While patients with RPLS may have areas of signal abnormality consistent with ischemia, these are usually superimposed on areas of increased ADC values. Patients with areas of decreased ADC values usually, but not always, progress to true infarction [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/2,8,14,72,83,84\" class=\"abstract_t\">2,8,14,72,83,84</a>]. A pseudonormalization of ADC values in areas of high DWI signal may be the earliest sign of permanent brain injury [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/2\" class=\"abstract_t\">2</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In one of the largest reported case series, the anatomical extent of MRI findings correlated with patient outcome [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/2\" class=\"abstract_t\">2</a>]. (See <a href=\"#H23\" class=\"local\">'Prognosis'</a> below.)</p><p/><p>Conventional angiography and magnetic resonance angiography (MRA) studies have documented vascular narrowing in patients with RPLS in a variety of clinical settings [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/85-92\" class=\"abstract_t\">85-92</a>]. This phenomenon is variably described as irregular in medium to large-sized vessels in some groups to diffuse and multisegmental in other groups [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/86\" class=\"abstract_t\">86</a>]. Prominent posterior circulation localization and reversibility of the findings are more consistently observed.</p><p>More advanced neuroimaging modalities such as diffusion-tensor imaging [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/15\" class=\"abstract_t\">15</a>], magnetic resonance spectroscopy [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/93\" class=\"abstract_t\">93</a>], single-photon emission computed tomography [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/20\" class=\"abstract_t\">20</a>], and perfusion-weighted MRI [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/13\" class=\"abstract_t\">13</a>] show promise as diagnostic tools in the evaluation of RPLS, particularly in the assessment of prognosis.</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are no specific diagnostic criteria for reversible posterior leukoencephalopathy syndrome (RPLS). In the appropriate clinical setting, clinicians should recognize the neurologic syndrome of headache, visual symptoms, confusion, and seizures and order a brain MRI. Diffusion-weighted imaging (DWI) if available, adds considerable diagnostic and prognostic information. (See <a href=\"#H15\" class=\"local\">'Neuroimaging'</a> above.)</p><p>Because the neuroradiographic findings after seizures or other neurologic conditions can be similar to those seen in RPLS, repeat neuroimaging may be necessary. With treatment, resolution of findings on neuroimaging within days to weeks is expected. Atypical MRI findings and treatment failure should prompt consideration of other diagnoses. (See <a href=\"#H38176987\" class=\"local\">'Differential diagnosis'</a> below.)</p><p class=\"headingAnchor\" id=\"H38176987\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The clinical findings are not specific for reversible posterior leukoencephalopathy syndrome (RPLS), which can resemble other neurologic conditions, such as stroke, venous thrombosis, toxic or metabolic encephalopathy, demyelinating disorders, vasculitis, or encephalitis among others [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/52,83,94\" class=\"abstract_t\">52,83,94</a>].</p><p>Particularly in cases with a sudden onset of neurologic symptoms, the presentation can mimic bilateral posterior cerebral artery infarctions (&quot;top of the basilar syndrome&quot;). It is important to distinguish between RPLS and ischemic stroke, as the treatment of hypertension may be very different in these conditions.</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h1\">PREVENTION AND TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Reversible posterior leukoencephalopathy syndrome (RPLS) should be promptly recognized, since it is usually reversible. Treating clinicians should have a high clinical suspicion in the appropriate settings (pregnancy, cytotoxic therapy, hypertensive patients), recognize the neurologic syndrome, and evaluate for RPLS with brain MRI.</p><p>Because of the heterogeneous clinical settings in which RPLS occurs and because clinical reports are limited to case reports and small series, treatment recommendations are somewhat limited.</p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h2\">Hypertension</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hypertension is a feature in the majority of RPLS patients, regardless of etiology [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/1,21,89,90,95,96\" class=\"abstract_t\">1,21,89,90,95,96</a>]. With blood pressure lowering, patients will often improve dramatically. Except in cases of malignant hypertension, patients with RPLS often present with only moderate levels of hypertension; in the majority of cases, however, this still represents a significant increase above baseline levels.</p><p>The initial aim of treatment in malignant hypertension is to rapidly lower the diastolic pressure to about 100 to 105 mmHg; this goal should be achieved within two to six hours, with the maximum initial fall in BP not exceeding 25 percent of the presenting value [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/97,98\" class=\"abstract_t\">97,98</a>]. (See <a href=\"topic.htm?path=moderate-to-severe-hypertensive-retinopathy-and-hypertensive-encephalopathy-in-adults\" class=\"medical medical_review\">&quot;Moderate to severe hypertensive retinopathy and hypertensive encephalopathy in adults&quot;</a>.) More aggressive blood pressure lowering is generally unnecessary and may reduce the blood pressure below the autoregulatory range, possibly leading to ischemic events (such as stroke or coronary disease) [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/99\" class=\"abstract_t\">99</a>].</p><p>For patients with lower levels of hypertension, lowering blood pressure is also recommended to treat RPLS, but no specific guidelines are suggested as discussed for malignant hypertension above. Using clinical symptoms and any prior knowledge of baseline blood pressure as a guide, careful, incremental downward titration in 10 to 25 percent increments of the mean arterial blood pressure seems a reasonable approach.</p><p>The use of easily titratable parenteral agents such as <a href=\"topic.htm?path=nicardipine-drug-information\" class=\"drug drug_general\">nicardipine</a>, <a href=\"topic.htm?path=labetalol-drug-information\" class=\"drug drug_general\">labetalol</a>, and <a href=\"topic.htm?path=nitroprusside-drug-information\" class=\"drug drug_general\">nitroprusside</a> are effective and safe in reducing the blood pressure to a desirable range [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/100\" class=\"abstract_t\">100</a>]. One caveat to the acute use of nitroprusside is the theoretical concern that it may paradoxically increase intracranial pressure through vasodilatation. We now generally use nitroprusside only when nicardipine and labetalol are not available, contraindicated, or ineffective. The pharmacology and other side effects of these agents are reviewed in detail elsewhere. (See <a href=\"topic.htm?path=drugs-used-for-the-treatment-of-hypertensive-emergencies\" class=\"medical medical_review\">&quot;Drugs used for the treatment of hypertensive emergencies&quot;</a>.)</p><p>Oral antihypertensive agents have a slower onset of action and are not usually effective in consistently lowering the blood pressure to an appropriate range in hypertensive crises to prevent and treat RPLS.</p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h2\">Seizures</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Except in the setting of eclampsia, most patients with RPLS and seizures are treated with <a href=\"topic.htm?path=phenytoin-drug-information\" class=\"drug drug_general\">phenytoin</a> [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/8,10,67\" class=\"abstract_t\">8,10,67</a>]. Other antiepileptic drugs may be just as effective and may be preferred, depending on the patient's other comorbid medical conditions and prescribed drugs [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/101\" class=\"abstract_t\">101</a>]. (See <a href=\"topic.htm?path=initial-treatment-of-epilepsy-in-adults\" class=\"medical medical_review\">&quot;Initial treatment of epilepsy in adults&quot;</a>.)</p><p>While long-term follow-up studies are limited, seizure recurrence or epilepsy appears to be rare. In one case series of 127 patients who had recovered from an episode of RPLS, unprovoked seizures occurred in 8 patients over a median 3.2 years of followup [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/102\" class=\"abstract_t\">102</a>]. </p><p>Although some case series report continuation of therapy for one to three months, <a href=\"topic.htm?path=phenytoin-drug-information\" class=\"drug drug_general\">phenytoin</a> can probably be safely tapered as symptoms and neuroimaging findings resolve, usually after one to two weeks [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/67\" class=\"abstract_t\">67</a>]. When recurrent, unprovoked seizures have occur after recovery from an RPLS episode, it is reasonable to resume or initiate antiepileptic drug therapy [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/100,102,103\" class=\"abstract_t\">100,102,103</a>].</p><p class=\"headingAnchor\" id=\"H20\"><span class=\"h2\">Eclampsia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Recommendations for the treatment of eclampsia differ from RPLS in other clinical settings. Delivery of the baby and placenta is often sufficient. Magnesium is used to treat seizures and is superior to <a href=\"topic.htm?path=phenytoin-drug-information\" class=\"drug drug_general\">phenytoin</a> and <a href=\"topic.htm?path=diazepam-drug-information\" class=\"drug drug_general\">diazepam</a> in this setting. The choice of antihypertensive drug is also influenced by concerns for placental function and fetal health. (See <a href=\"topic.htm?path=eclampsia\" class=\"medical medical_review\">&quot;Eclampsia&quot;</a> and <a href=\"topic.htm?path=management-of-hypertension-in-pregnant-and-postpartum-women\" class=\"medical medical_review\">&quot;Management of hypertension in pregnant and postpartum women&quot;</a> and <a href=\"topic.htm?path=preeclampsia-management-and-prognosis\" class=\"medical medical_review\">&quot;Preeclampsia: Management and prognosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H21\"><span class=\"h2\">Cytotoxic immunosuppressive therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Reduction in drug dosage or prompt removal of the cytotoxic drug is usually recommended in cases of RPLS associated with cytotoxic agents and is often associated with clinical improvement [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/104-106\" class=\"abstract_t\">104-106</a>]. However, cases are reported in which symptoms resolve while the medication is maintained [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/49\" class=\"abstract_t\">49</a>]. When another immunosuppressive agent is substituted, patients must be followed closely for recurrence of RPLS. It is not recommended that agents known to induce RPLS be reintroduced, as recurrence has been reported in this setting [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/2,54\" class=\"abstract_t\">2,54</a>].</p><p>Based on two cases and a literature review of RPLS in the setting of cytotoxic chemotherapy administration, authors suggest that patients with one or more of the following are at risk of RPLS [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/107\" class=\"abstract_t\">107</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Significant fluid overload (&gt;10 percent of baseline weight)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Mean blood pressure &gt;25 percent of baseline</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Creatinine &gt;1.8 <span class=\"nowrap\">mg/dL</span> (160 <span class=\"nowrap\">&micro;mol/L)</span></p><p/><p>In these patients, weight changes and blood pressure should be followed closely during aggressive fluid resuscitation (&gt;3 L of daily intravenous fluid). Although the number of cases was small, this marks one of the few attempts to focus on specific guidelines for treatment and may prove useful as a general means of preventing RPLS.</p><p class=\"headingAnchor\" id=\"H22\"><span class=\"h2\">Other</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Because comorbid conditions including electrolyte disturbances, fluid overload, uremia, and sepsis are suggested to contribute to the development and prognosis in patients with RPLS, aggressive screening for and treatment of these conditions is recommended. In at least one case, aggressive dialysis appeared to influence the course of a patient with otherwise poor prognostic factors [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/2\" class=\"abstract_t\">2</a>].</p><p>Treatment of thrombotic thrombocytopenic purpura with plasmapheresis or immunoglobulin has resulted in resolution of RPLS. </p><p>Patients with RPLS have been treated with decadron [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/8,108\" class=\"abstract_t\">8,108</a>], but because of its associated risk of hypertension, fluid overload, and electrolyte disturbance as well as the fact that high-dose steroid therapy has been associated with the development of RPLS, this is not a recommended therapy.</p><p class=\"headingAnchor\" id=\"H23\"><span class=\"h1\">PROGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most case series and case reports suggest that reversible posterior leukoencephalopathy syndrome (RPLS) is usually benign. In many cases, RPLS seems to be fully reversible within a period of days to weeks, after removal of the inciting factor and control of the blood pressure [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/1,7,44,45,65,109\" class=\"abstract_t\">1,7,44,45,65,109</a>]. Radiologic improvement lags behind clinical recovery.</p><p>However, one of the largest case series reported highlights the potential grave consequences of this disorder; among 22 patients studied, six died and many survivors had permanent neurologic disability [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/2\" class=\"abstract_t\">2</a>]. Death may result from progressive cerebral edema, intracerebral hemorrhage, or as a complication of the underlying condition [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/2,8,10\" class=\"abstract_t\">2,8,10</a>]. In one series, elevated creatinine levels were a risk factor for death, but neither blood pressure levels or percent elevation from baseline values appeared to correlate with prognosis [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/2\" class=\"abstract_t\">2</a>]. MRI findings of hyperintense signals on DWI and restricted diffusion on ADC mapping suggest cytotoxic as opposed to vasogenic edema; these findings seem to be predictive of irreversible infarction and in turn a worse prognosis [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/2\" class=\"abstract_t\">2</a>]. More extensive brain involvement, particularly in the brainstem also correlates with a worse prognosis.</p><p>Recurrence of RPLS appears to be infrequent, 2 of 25 patients in one series, despite the fact that inciting factors commonly recur in these patients [<a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/109\" class=\"abstract_t\">109</a>].</p><p>Some patients develop unprovoked seizures and epilepsy after recovering from RPLS, but this appears to be rare. (See <a href=\"#H19\" class=\"local\">'Seizures'</a> above.)</p><p class=\"headingAnchor\" id=\"H24\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Reversible posterior leukoencephalopathy syndrome (RPLS) is a neurologic syndrome defined by clinical and radiologic features.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The typical clinical syndrome includes headache, confusion, visual symptoms, and seizures. (See <a href=\"#H13\" class=\"local\">'Clinical manifestations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Typical MRI findings are consistent with vasogenic edema and are predominantly localized to the posterior cerebral hemispheres. DWI can be helpful in distinguishing RPLS from stroke. (See <a href=\"#H15\" class=\"local\">'Neuroimaging'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>RPLS most often occurs in the setting of hypertensive crisis, preeclampsia, or with cytotoxic immunosuppressive therapy; however, many other clinical settings are described. (See <a href=\"#H9\" class=\"local\">'Associated conditions'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We recommend lowering blood pressure in all patients with RPLS (<a href=\"grade.htm?i=2\" class=\"grade\">Grade 1B</a>). An easily titratable parenteral agent such as <a href=\"topic.htm?path=nicardipine-drug-information\" class=\"drug drug_general\">nicardipine</a> or <a href=\"topic.htm?path=labetalol-drug-information\" class=\"drug drug_general\">labetalol</a> is suggested. Even patients with seemingly normal blood pressure benefit from blood pressure lowering as their baseline blood pressure may be much lower. (See <a href=\"#H18\" class=\"local\">'Hypertension'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We suggest withdrawing or lowering the dose of the offending cytotoxic agent, permanently if possible (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). When another immunosuppressive agent is substituted, patients must be followed closely for recurrence of RPLS. (See <a href=\"#H21\" class=\"local\">'Cytotoxic immunosuppressive therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We suggest treating patients who have a seizure with antiepileptic drugs (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). We typically use an intravenous agent such as <a href=\"topic.htm?path=phenytoin-drug-information\" class=\"drug drug_general\">phenytoin</a>. The risk of late recurrence or epilepsy after uncomplicated RPLS appears low. As a result, we suggest that phenytoin be discontinued after symptoms and neuroimaging findings resolve (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). (See <a href=\"#H19\" class=\"local\">'Seizures'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In the partum or postpartum setting, we recommend treating patients with RPLS as though they have preeclampsia or eclampsia (<a href=\"grade.htm?i=3\" class=\"grade\">Grade 1C</a>). (See <a href=\"topic.htm?path=preeclampsia-management-and-prognosis\" class=\"medical medical_review\">&quot;Preeclampsia: Management and prognosis&quot;</a> and <a href=\"topic.htm?path=management-of-hypertension-in-pregnant-and-postpartum-women\" class=\"medical medical_review\">&quot;Management of hypertension in pregnant and postpartum women&quot;</a> and <a href=\"topic.htm?path=eclampsia\" class=\"medical medical_review\">&quot;Eclampsia&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Most patients recover within two weeks. A small number have residual neurologic deficits resulting from secondary cerebral infarction or hemorrhage; some patients die as a result of increased intracranial pressure or as a complication of the underlying condition. MRI findings can be helpful in identifying patients with worse prognosis. (See <a href=\"#H23\" class=\"local\">'Prognosis'</a> above.)</p><p/><p/><p class=\"headingAnchor\" id=\"H1336824701\"><span class=\"h1\">ACKNOWLEDGMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The editorial staff at UpToDate, Inc. would like to acknowledge Dr. J Claude Hemphill, III, who contributed to an earlier version of this topic review. </p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/1\" class=\"nounderline abstract_t\">Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996; 334:494.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/2\" class=\"nounderline abstract_t\">Covarrubias DJ, Luetmer PH, Campeau NG. Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images. AJNR Am J Neuroradiol 2002; 23:1038.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/3\" class=\"nounderline abstract_t\">Kwon S, Koo J, Lee S. Clinical spectrum of reversible posterior leukoencephalopathy syndrome. Pediatr Neurol 2001; 24:361.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/4\" class=\"nounderline abstract_t\">Antunes NL, Small TN, George D, et al. Posterior leukoencephalopathy syndrome may not be reversible. Pediatr Neurol 1999; 20:241.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/5\" class=\"nounderline abstract_t\">Alehan F, Erol I, Agildere AM, et al. Posterior leukoencephalopathy syndrome in children and adolescents. J Child Neurol 2007; 22:406.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/6\" class=\"nounderline abstract_t\">Chen TH, Lin WC, Tseng YH, et al. Posterior Reversible Encephalopathy Syndrome in Children: Case Series and Systematic Review. J Child Neurol 2013; 28:1378.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/7\" class=\"nounderline abstract_t\">Raj S, Overby P, Erdfarb A, Ushay HM. Posterior reversible encephalopathy syndrome: incidence and associated factors in a pediatric critical care population. Pediatr Neurol 2013; 49:335.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/8\" class=\"nounderline abstract_t\">Ay H, Buonanno FS, Schaefer PW, et al. Posterior leukoencephalopathy without severe hypertension: utility of diffusion-weighted MRI. Neurology 1998; 51:1369.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/9\" class=\"nounderline abstract_t\">Provenzale JM, Petrella JR, Cruz LC Jr, et al. Quantitative assessment of diffusion abnormalities in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol 2001; 22:1455.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/10\" class=\"nounderline abstract_t\">Stott VL, Hurrell MA, Anderson TJ. Reversible posterior leukoencephalopathy syndrome: a misnomer reviewed. Intern Med J 2005; 35:83.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/11\" class=\"nounderline abstract_t\">Strandgaard S, Paulson OB. Cerebral autoregulation. Stroke 1984; 15:413.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/12\" class=\"nounderline abstract_t\">Paulson OB, Strandgaard S, Edvinsson L. Cerebral autoregulation. Cerebrovasc Brain Metab Rev 1990; 2:161.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/13\" class=\"nounderline abstract_t\">Jones BV, Egelhoff JC, Patterson RJ. Hypertensive encephalopathy in children. AJNR Am J Neuroradiol 1997; 18:101.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/14\" class=\"nounderline abstract_t\">Koch S, Rabinstein A, Falcone S, Forteza A. Diffusion-weighted imaging shows cytotoxic and vasogenic edema in eclampsia. AJNR Am J Neuroradiol 2001; 22:1068.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/15\" class=\"nounderline abstract_t\">Mukherjee P, McKinstry RC. Reversible posterior leukoencephalopathy syndrome: evaluation with diffusion-tensor MR imaging. Radiology 2001; 219:756.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/16\" class=\"nounderline abstract_t\">Lewis LK, Hinshaw DB Jr, Will AD, et al. CT and angiographic correlation of severe neurological disease in toxemia of pregnancy. Neuroradiology 1988; 30:59.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/17\" class=\"nounderline abstract_t\">Naidu K, Moodley J, Corr P, Hoffmann M. Single photon emission and cerebral computerised tomographic scan and transcranial Doppler sonographic findings in eclampsia. Br J Obstet Gynaecol 1997; 104:1165.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/18\" class=\"nounderline abstract_t\">Tajima Y, Isonishi K, Kashiwaba T, Tashiro K. Two similar cases of encephalopathy, possibly a reversible posterior leukoencephalopathy syndrome: serial findings of magnetic resonance imaging, SPECT and angiography. Intern Med 1999; 38:54.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/19\" class=\"nounderline abstract_t\">Lanzino G, Cloft H, Hemstreet MK, et al. Reversible posterior leukoencephalopathy following organ transplantation. Description of two cases. Clin Neurol Neurosurg 1997; 99:222.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/20\" class=\"nounderline abstract_t\">Schwartz RB, Jones KM, Kalina P, et al. Hypertensive encephalopathy: findings on CT, MR imaging, and SPECT imaging in 14 cases. AJR Am J Roentgenol 1992; 159:379.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/21\" class=\"nounderline abstract_t\">Ito Y, Arahata Y, Goto Y, et al. Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome. AJNR Am J Neuroradiol 1998; 19:415.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/22\" class=\"nounderline abstract_t\">Schwartz RB, Feske SK, Polak JF, et al. Preeclampsia-eclampsia: clinical and neuroradiographic correlates and insights into the pathogenesis of hypertensive encephalopathy. Radiology 2000; 217:371.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/23\" class=\"nounderline abstract_t\">Savvidou MD, Hingorani AD, Tsikas D, et al. Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia. Lancet 2003; 361:1511.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/24\" class=\"nounderline abstract_t\">Easton JD. Severe preeclampsia/eclampsia: hypertensive encephalopathy of pregnancy? Cerebrovasc Dis 1998; 8:53.</a></li><li class=\"breakAll\">Lindenbaum J. An approach to the anemias. In: Cecil's Textbook of Medicine, Bennett JC, Plum F (Eds), Philadelphia 1996. p.823.</li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/26\" class=\"nounderline abstract_t\">Rodgers GM, Taylor RN, Roberts JM. Preeclampsia is associated with a serum factor cytotoxic to human endothelial cells. Am J Obstet Gynecol 1988; 159:908.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/27\" class=\"nounderline abstract_t\">Blann AD, Taberner DA. A reliable marker of endothelial cell dysfunction: does it exist? Br J Haematol 1995; 90:244.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/28\" class=\"nounderline abstract_t\">Roberts JM, Redman CW. Pre-eclampsia: more than pregnancy-induced hypertension. Lancet 1993; 341:1447.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/29\" class=\"nounderline abstract_t\">Burrus TM, Mandrekar J, Wijdicks EF, Rabinstein AA. Renal failure and posterior reversible encephalopathy syndrome in patients with thrombotic thrombocytopenic purpura. Arch Neurol 2010; 67:831.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/30\" class=\"nounderline abstract_t\">Hawley JS, Ney JP, Swanberg MM. Thrombotic thrombocytopenic purpura-induced posterior leukoencephalopathy in a patient without significant renal or hypertensive complications. J Postgrad Med 2004; 50:197.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/31\" class=\"nounderline abstract_t\">Brightman MW, Klatzo I, Olsson Y, Reese TS. The blood-brain barrier to proteins under normal and pathological conditions. J Neurol Sci 1970; 10:215.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/32\" class=\"nounderline abstract_t\">Kalimo H, Fredriksson K, Nordborg C, et al. The spread of brain oedema in hypertensive brain injury. Med Biol 1986; 64:133.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/33\" class=\"nounderline abstract_t\">Beausang-Linder M, Bill A. Cerebral circulation in acute arterial hypertension--protective effects of sympathetic nervous activity. Acta Physiol Scand 1981; 111:193.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/34\" class=\"nounderline abstract_t\">Edvinsson L, Owman C, Sj&ouml;berg NO. Autonomic nerves, mast cells, and amine receptors in human brain vessels. A histochemical and pharmacological study. Brain Res 1976; 115:377.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/35\" class=\"nounderline abstract_t\">Lamy C, Oppenheim C, M&eacute;der JF, Mas JL. Neuroimaging in posterior reversible encephalopathy syndrome. J Neuroimaging 2004; 14:89.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/36\" class=\"nounderline abstract_t\">Fugate JE, Claassen DO, Cloft HJ, et al. Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc 2010; 85:427.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/37\" class=\"nounderline abstract_t\">Staykov D, Schwab S. Posterior reversible encephalopathy syndrome. J Intensive Care Med 2012; 27:11.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/38\" class=\"nounderline abstract_t\">Maga&ntilde;a SM, Matiello M, Pittock SJ, et al. Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology 2009; 72:712.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/39\" class=\"nounderline abstract_t\">Barton JR, Sibai BM. Cerebral pathology in eclampsia. Clin Perinatol 1991; 18:891.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/40\" class=\"nounderline abstract_t\">Schaefer PW, Buonanno FS, Gonzalez RG, Schwamm LH. Diffusion-weighted imaging discriminates between cytotoxic and vasogenic edema in a patient with eclampsia. Stroke 1997; 28:1082.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/41\" class=\"nounderline abstract_t\">Schwartz RB, Mulkern RV, Gudbjartsson H, Jolesz F. Diffusion-weighted MR imaging in hypertensive encephalopathy: clues to pathogenesis. AJNR Am J Neuroradiol 1998; 19:859.</a></li><li class=\"breakAll\">Lamy C, Mas JL. Hypertensive encephalopathy. In: Stroke: Pathophysiology, Diagnosis, and Management, 4th, Mohr JP, Choi D, Grotta J, et al (Eds), Churchill Livingstone, New York 2004. Vol 2004.</li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/43\" class=\"nounderline abstract_t\">Bartynski WS. Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features. AJNR Am J Neuroradiol 2008; 29:1036.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/44\" class=\"nounderline abstract_t\">Leroux G, Sellam J, Costedoat-Chalumeau N, et al. Posterior reversible encephalopathy syndrome during systemic lupus erythematosus: four new cases and review of the literature. Lupus 2008; 17:139.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/45\" class=\"nounderline abstract_t\">Mak A, Chan BP, Yeh IB, et al. Neuropsychiatric lupus and reversible posterior leucoencephalopathy syndrome: a challenging clinical dilemma. Rheumatology (Oxford) 2008; 47:256.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/46\" class=\"nounderline abstract_t\">Hodson AK, Doughty RA, Norman ME. Acute encephalopathy, streptococcal infection, and cryoglobulinemia. Arch Neurol 1978; 35:43.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/47\" class=\"nounderline abstract_t\">Port JD, Beauchamp NJ Jr. Reversible intracerebral pathologic entities mediated by vascular autoregulatory dysfunction. Radiographics 1998; 18:353.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/48\" class=\"nounderline abstract_t\">Magnano MD, Bush TM, Herrera I, Altman RD. Reversible posterior leukoencephalopathy in patients with systemic lupus erythematosus. Semin Arthritis Rheum 2006; 35:396.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/49\" class=\"nounderline abstract_t\">Schwartz RB, Bravo SM, Klufas RA, et al. Cyclosporine neurotoxicity and its relationship to hypertensive encephalopathy: CT and MR findings in 16 cases. AJR Am J Roentgenol 1995; 165:627.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/50\" class=\"nounderline abstract_t\">Dinsdale HB. Hypertensive encephalopathy. Neurol Clin 1983; 1:3.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/51\" class=\"nounderline abstract_t\">Garg RK. Posterior leukoencephalopathy syndrome. Postgrad Med J 2001; 77:24.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/52\" class=\"nounderline abstract_t\">Raps EC, Galetta SL, Broderick M, Atlas SW. Delayed peripartum vasculopathy: cerebral eclampsia revisited. Ann Neurol 1993; 33:222.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/53\" class=\"nounderline abstract_t\">Ille O, Woimant F, Pruna A, et al. Hypertensive encephalopathy after bilateral carotid endarterectomy. Stroke 1995; 26:488.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/54\" class=\"nounderline abstract_t\">Serkova NJ, Christians U, Benet LZ. Biochemical mechanisms of cyclosporine neurotoxicity. Mol Interv 2004; 4:97.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/55\" class=\"nounderline abstract_t\">Kou R, Greif D, Michel T. Dephosphorylation of endothelial nitric-oxide synthase by vascular endothelial growth factor. Implications for the vascular responses to cyclosporin A. J Biol Chem 2002; 277:29669.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/56\" class=\"nounderline abstract_t\">Beal MF. Mitochondrial dysfunction in neurodegenerative diseases. Biochim Biophys Acta 1998; 1366:211.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/57\" class=\"nounderline abstract_t\">Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006; 354:980.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/58\" class=\"nounderline abstract_t\">Ozcan C, Wong SJ, Hari P. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006; 354:980.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/59\" class=\"nounderline abstract_t\">Allen JA, Adlakha A, Bergethon PR. Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol 2006; 63:1475.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/60\" class=\"nounderline abstract_t\">Bodkin CL, Eidelman BH. Sirolimus-induced posterior reversible encephalopathy. Neurology 2007; 68:2039.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/61\" class=\"nounderline abstract_t\">Rajasekhar A, George TJ Jr. Gemcitabine-induced reversible posterior leukoencephalopathy syndrome: a case report and review of the literature. Oncologist 2007; 12:1332.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/62\" class=\"nounderline abstract_t\">Junna MR, Rabinstein AA. Tacrolimus induced leukoencephalopathy presenting with status epilepticus and prolonged coma. J Neurol Neurosurg Psychiatry 2007; 78:1410.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/63\" class=\"nounderline abstract_t\">Kozak OS, Wijdicks EF, Manno EM, et al. Status epilepticus as initial manifestation of posterior reversible encephalopathy syndrome. Neurology 2007; 69:894.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/64\" class=\"nounderline abstract_t\">Seet RC, Rabinstein AA. Clinical features and outcomes of posterior reversible encephalopathy syndrome following bevacizumab treatment. QJM 2012; 105:69.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/65\" class=\"nounderline abstract_t\">Lee VH, Wijdicks EF, Manno EM, Rabinstein AA. Clinical spectrum of reversible posterior leukoencephalopathy syndrome. Arch Neurol 2008; 65:205.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/66\" class=\"nounderline abstract_t\">Kastrup O, Gerwig M, Frings M, Diener HC. Posterior reversible encephalopathy syndrome (PRES): electroencephalographic findings and seizure patterns. J Neurol 2012; 259:1383.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/67\" class=\"nounderline abstract_t\">Bakshi R, Bates VE, Mechtler LL, et al. Occipital lobe seizures as the major clinical manifestation of reversible posterior leukoencephalopathy syndrome: magnetic resonance imaging findings. Epilepsia 1998; 39:295.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/68\" class=\"nounderline abstract_t\">Lysandropoulos AP, Rossetti AO. Postictal cortical visual impairment: a symptom of posterior reversible encephalopathy. Epilepsy Behav 2010; 17:276.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/69\" class=\"nounderline abstract_t\">Keswani SC, Wityk R. Don't throw in the towel! A case of reversible coma. J Neurol Neurosurg Psychiatry 2002; 73:83.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/70\" class=\"nounderline abstract_t\">de Havenon A, Joos Z, Longenecker L, et al. Posterior reversible encephalopathy syndrome with spinal cord involvement. Neurology 2014; 83:2002.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/71\" class=\"nounderline abstract_t\">McKinney AM, Jagadeesan BD, Truwit CL. Central-variant posterior reversible encephalopathy syndrome: brainstem or basal ganglia involvement lacking cortical or subcortical cerebral edema. AJR Am J Roentgenol 2013; 201:631.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/72\" class=\"nounderline abstract_t\">Wang MC, Escott EJ, Breeze RE. Posterior fossa swelling and hydrocephalus resulting from hypertensive encephalopathy: case report and review of the literature. Neurosurgery 1999; 44:1325.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/73\" class=\"nounderline abstract_t\">de Seze J, Mastain B, Stojkovic T, et al. Unusual MR findings of the brain stem in arterial hypertension. AJNR Am J Neuroradiol 2000; 21:391.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/74\" class=\"nounderline abstract_t\">Oliverio PJ, Restrepo L, Mitchell SA, et al. Reversible tacrolimus-induced neurotoxicity isolated to the brain stem. AJNR Am J Neuroradiol 2000; 21:1251.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/75\" class=\"nounderline abstract_t\">Kitaguchi H, Tomimoto H, Miki Y, et al. A brainstem variant of reversible posterior leukoencephalopathy syndrome. Neuroradiology 2005; 47:652.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/76\" class=\"nounderline abstract_t\">Meylaerts L, Ooms V, Lyra S, et al. Hypertensive brain stem encephalopathy in a patient with chronic renal failure. Clin Nephrol 2006; 65:138.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/77\" class=\"nounderline abstract_t\">Friese S, Fetter M, K&uuml;ker W. Extensive brainstem edema in eclampsia: diffusion-weighted MRI may indicate a favorable prognosis. J Neurol 2000; 247:465.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/78\" class=\"nounderline abstract_t\">Lapuyade B, Sibon I, Jeanin S, Dousset V. Neurological picture. Spinal cord involvement in posterior reversible encephalopathy syndrome. J Neurol Neurosurg Psychiatry 2009; 80:35.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/79\" class=\"nounderline abstract_t\">Briganti C, Caulo M, Notturno F, et al. Asymptomatic spinal cord involvement in posterior reversible encephalopathy syndrome. Neurology 2009; 73:1507.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/80\" class=\"nounderline abstract_t\">Digre KB, Varner MW, Osborn AG, Crawford S. Cranial magnetic resonance imaging in severe preeclampsia vs eclampsia. Arch Neurol 1993; 50:399.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/81\" class=\"nounderline abstract_t\">Weingarten K, Barbut D, Filippi CG, Zimmerman RD. Acute hypertensive encephalopathy: findings on spin-echo and gradient-echo MR imaging. AJR Am J Roentgenol 1994; 162:665.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/82\" class=\"nounderline abstract_t\">Oppenheim C, Logak M, Dormont D, et al. Diagnosis of acute ischaemic stroke with fluid-attenuated inversion recovery and diffusion-weighted sequences. Neuroradiology 2000; 42:602.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/83\" class=\"nounderline abstract_t\">Oppenheim C, Galanaud D, Samson Y, et al. Can diffusion weighted magnetic resonance imaging help differentiate stroke from stroke-like events in MELAS? J Neurol Neurosurg Psychiatry 2000; 69:248.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/84\" class=\"nounderline abstract_t\">Trommer BL, Homer D, Mikhael MA. Cerebral vasospasm and eclampsia. Stroke 1988; 19:326.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/85\" class=\"nounderline abstract_t\">Heo K, Park S, Lee JY, et al. Post-transfusion posterior leukoencephalopathy with cytotoxic and vasogenic edema precipitated by vasospasm. Cerebrovasc Dis 2003; 15:230.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/86\" class=\"nounderline abstract_t\">Will AD, Lewis KL, Hinshaw DB Jr, et al. Cerebral vasoconstriction in toxemia. Neurology 1987; 37:1555.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/87\" class=\"nounderline abstract_t\">Kaplan PW. Reversible hypercalcemic cerebral vasoconstriction with seizures and blindness: a paradigm for eclampsia? Clin Electroencephalogr 1998; 29:120.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/88\" class=\"nounderline abstract_t\">Voltz R, Rosen FV, Yousry T, et al. Reversible encephalopathy with cerebral vasospasm in a Guillain-Barr&eacute; syndrome patient treated with intravenous immunoglobulin. Neurology 1996; 46:250.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/89\" class=\"nounderline abstract_t\">Henderson RD, Rajah T, Nicol AJ, Read SJ. Posterior leukoencephalopathy following intrathecal chemotherapy with MRA-documented vasospasm. Neurology 2003; 60:326.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/90\" class=\"nounderline abstract_t\">Ito Y, Niwa H, Iida T, et al. Post-transfusion reversible posterior leukoencephalopathy syndrome with cerebral vasoconstriction. Neurology 1997; 49:1174.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/91\" class=\"nounderline abstract_t\">Boughammoura A, Touz&eacute; E, Oppenheim C, et al. Reversible angiopathy and encephalopathy after blood transfusion. J Neurol 2003; 250:116.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/92\" class=\"nounderline abstract_t\">Eichler FS, Wang P, Wityk RJ, et al. Diffuse metabolic abnormalities in reversible posterior leukoencephalopathy syndrome. AJNR Am J Neuroradiol 2002; 23:833.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/93\" class=\"nounderline abstract_t\">Delanty N, Vaughan C, Frucht S, Stubgen P. Erythropoietin-associated hypertensive posterior leukoencephalopathy. Neurology 1997; 49:686.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/94\" class=\"nounderline abstract_t\">Casey SO, Sampaio RC, Michel E, Truwit CL. Posterior reversible encephalopathy syndrome: utility of fluid-attenuated inversion recovery MR imaging in the detection of cortical and subcortical lesions. AJNR Am J Neuroradiol 2000; 21:1199.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/95\" class=\"nounderline abstract_t\">Kupferschmidt H, Bont A, Schnorf H, et al. Transient cortical blindness and bioccipital brain lesions in two patients with acute intermittent porphyria. Ann Intern Med 1995; 123:598.</a></li><li class=\"breakAll\">Kaplan, NM. Hypertensive crises. In: Clinical Hypertension, 7th, Kaplan NM (Ed), Williams &amp; Wilkins, Baltimore 1998. p.265.</li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/97\" class=\"nounderline abstract_t\">Vaughan CJ, Delanty N. Hypertensive emergencies. Lancet 2000; 356:411.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/98\" class=\"nounderline abstract_t\">Ledingham JG, Rajagopalan B. Cerebral complications in the treatment of accelerated hypertension. Q J Med 1979; 48:25.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/99\" class=\"nounderline abstract_t\">Neutel JM, Smith DH, Wallin D, et al. A comparison of intravenous nicardipine and sodium nitroprusside in the immediate treatment of severe hypertension. Am J Hypertens 1994; 7:623.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/100\" class=\"nounderline abstract_t\">Arnoldus EP, Van Laar T. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996; 334:1745; author reply 1746.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/101\" class=\"nounderline abstract_t\">Eberly AL, Anderson GD, Bubalo JS, McCune JS. Optimal prevention of seizures induced by high-dose busulfan. Pharmacotherapy 2008; 28:1502.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/102\" class=\"nounderline abstract_t\">Datar S, Singh T, Rabinstein AA, et al. Long-term risk of seizures and epilepsy in patients with posterior reversible encephalopathy syndrome. Epilepsia 2015; 56:564.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/103\" class=\"nounderline abstract_t\">Baldini M, Bartolini E, Gori S, et al. Epilepsy after neuroimaging normalization in a woman with tacrolimus-related posterior reversible encephalopathy syndrome. Epilepsy Behav 2010; 17:558.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/104\" class=\"nounderline abstract_t\">Gijtenbeek JM, van den Bent MJ, Vecht CJ. Cyclosporine neurotoxicity: a review. J Neurol 1999; 246:339.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/105\" class=\"nounderline abstract_t\">Hauben M. Cyclosporine neurotoxicity. Pharmacotherapy 1996; 16:576.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/106\" class=\"nounderline abstract_t\">Hayes D Jr, Adler B, Turner TL, Mansour HM. Alternative tacrolimus and sirolimus regimen associated with rapid resolution of posterior reversible encephalopathy syndrome after lung transplantation. Pediatr Neurol 2014; 50:272.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/107\" class=\"nounderline abstract_t\">Tam CS, Galanos J, Seymour JF, et al. Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignancies. Am J Hematol 2004; 77:72.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/108\" class=\"nounderline abstract_t\">Eaton JM. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996; 334:1744.</a></li><li><a href=\"https://www.uptodate.com/contents/reversible-posterior-leukoencephalopathy-syndrome/abstract/109\" class=\"nounderline abstract_t\">Roth C, Ferbert A. Posterior reversible encephalopathy syndrome: long-term follow-up. J Neurol Neurosurg Psychiatry 2010; 81:773.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 4835 Version 10.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H24\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H712827215\" id=\"outline-link-H712827215\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">EPIDEMIOLOGY</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">PATHOGENESIS</a><ul><li><a href=\"#H4\" id=\"outline-link-H4\">Autoregulatory failure</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Cerebral ischemia</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">Endothelial dysfunction</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">Other mechanisms</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Anatomic distribution</a></li></ul></li><li><a href=\"#H9\" id=\"outline-link-H9\">ASSOCIATED CONDITIONS</a><ul><li><a href=\"#H10\" id=\"outline-link-H10\">Hypertension</a><ul><li><a href=\"#H11\" id=\"outline-link-H11\">- Eclampsia</a></li></ul></li><li><a href=\"#H12\" id=\"outline-link-H12\">Immunosuppressive therapy</a></li><li><a href=\"#H271180842\" id=\"outline-link-H271180842\">Others</a></li></ul></li><li><a href=\"#H13\" id=\"outline-link-H13\">CLINICAL MANIFESTATIONS</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">NEUROIMAGING</a></li><li><a href=\"#H16\" id=\"outline-link-H16\">DIAGNOSIS</a></li><li><a href=\"#H38176987\" id=\"outline-link-H38176987\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H17\" id=\"outline-link-H17\">PREVENTION AND TREATMENT</a><ul><li><a href=\"#H18\" id=\"outline-link-H18\">Hypertension</a></li><li><a href=\"#H19\" id=\"outline-link-H19\">Seizures</a></li><li><a href=\"#H20\" id=\"outline-link-H20\">Eclampsia</a></li><li><a href=\"#H21\" id=\"outline-link-H21\">Cytotoxic immunosuppressive therapy</a></li><li><a href=\"#H22\" id=\"outline-link-H22\">Other</a></li></ul></li><li><a href=\"#H23\" id=\"outline-link-H23\">PROGNOSIS</a></li><li><a href=\"#H24\" id=\"outline-link-H24\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#H1336824701\" id=\"outline-link-H1336824701\">ACKNOWLEDGMENT</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"NEURO/4835|DiagnosticImage\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"DIAGNOSTIC IMAGES\">DIAGNOSTIC IMAGES</a></div><ul><li><a href=\"image.htm?imageKey=NEURO/79338\" class=\"graphic graphic_diagnosticimage\">- RPL CT and MRI findings A</a></li><li><a href=\"image.htm?imageKey=NEURO/56979\" class=\"graphic graphic_diagnosticimage\">- RPL CT and MRI findings B</a></li><li><a href=\"image.htm?imageKey=NEURO/70704\" class=\"graphic graphic_diagnosticimage\">- Distal basilar artery embolism</a></li></ul></li><li><div id=\"NEURO/4835|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=NEURO/67583\" class=\"graphic graphic_figure\">- Norm autoregulation cereb</a></li><li><a href=\"image.htm?imageKey=NEPH/57676\" class=\"graphic graphic_figure\">- Cerebral autoregulation in hypertension</a></li></ul></li><li><div id=\"NEURO/4835|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=NEURO/51758\" class=\"graphic graphic_table\">- Medical conditions with RPLS</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=drugs-used-for-the-treatment-of-hypertensive-emergencies\" class=\"medical medical_review\">Drugs used for the treatment of hypertensive emergencies</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=eclampsia\" class=\"medical medical_review\">Eclampsia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=initial-treatment-of-epilepsy-in-adults\" class=\"medical medical_review\">Initial treatment of epilepsy in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-hypertension-in-pregnant-and-postpartum-women\" class=\"medical medical_review\">Management of hypertension in pregnant and postpartum women</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=moderate-to-severe-hypertensive-retinopathy-and-hypertensive-encephalopathy-in-adults\" class=\"medical medical_review\">Moderate to severe hypertensive retinopathy and hypertensive encephalopathy in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pharmacology-of-cyclosporine-and-tacrolimus\" class=\"medical medical_review\">Pharmacology of cyclosporine and tacrolimus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=preeclampsia-management-and-prognosis\" class=\"medical medical_review\">Preeclampsia: Management and prognosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=preeclampsia-pathogenesis\" class=\"medical medical_review\">Preeclampsia: Pathogenesis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=toxicity-of-molecularly-targeted-antiangiogenic-agents-non-cardiovascular-effects\" class=\"medical medical_review\">Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects</a></li></ul></div></div>","javascript":null}